Elan temettüsü güvende mi?
Elan, 9 yıldır temettüsünü artırıyor.
Son 10 yıl içerisinde Elan, yıllık %46,261 artırılmış arttırdı.
5 yıllık sürede arttı, dağıtımını %25,482 oranında artırdı.
Analistler, mevcut mali yıl için %7,731 oranında bir Temettü Artışı bekliyorlar.
Elan Aktienanalyse
Elan ne yapıyor?
Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name.
In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease.
Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success.
Elan Corp consists of three main business areas:
1. Biopharmaceuticals
This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients.
2. Neurology
In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections.
3. Medical Technology
Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market.
Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan, Eulerpool.com'da en popüler şirketlerden biridir.Aktiensparpläne, yatırımcıların uzun vadeli olarak servet inşa etmeleri için çekici bir fırsat sunar. Ana avantajlardan biri, sözde Cost-Average-Effekti'dir: Düzenli olarak sabit bir miktarın hisse senetlerine veya hisse senedi fonlarına yatırılmasıyla, fiyatlar düşükken otomatik olarak daha fazla pay alınır ve fiyatlar yüksekken daha az alınır. Bu, zaman içinde hisse başına daha uygun bir ortalama fiyata yol açabilir. Ayrıca, Aktiensparpläne, küçük miktarlarla bile pahalı hisselere erişim sağlayarak küçük yatırımcılara da kapılarını açar. Düzenli yatırım, ayrıca disiplinli bir yatırım stratejisini teşvik eder ve impulsif alım veya satım gibi duygusal kararları engellemeye yardımcı olur. Bunun ötesinde, yatırımcılar hisselerin potansiyel değer artışından ve yeniden yatırılabilecek temettü dağıtımlarından faydalanır, bu da bileşik faiz etkisini ve böylece yatırılan sermayenin büyümesini artırır.